GSH and analogs in antiviral therapy

Department of Biomolecular Sciences, University of Urbino Carlo Bo, Via Saffi 2, 61029 Urbino, PU, Italy.
Molecular Aspects of Medicine (Impact Factor: 10.24). 10/2008; 30(1-2):99-110. DOI: 10.1016/j.mam.2008.09.001
Source: PubMed


Reduced glutathione (GSH) is the most prevalent non-protein thiol in animal cells. Its de novo and salvage synthesis serves to maintain a reduced cellular environment. GSH is the most powerful intracellular antioxidant and plays a role in the detoxification of a variety of electrophilic compounds and peroxides via catalysis by glutathione-S-transferases (GST) and glutathione peroxidases (GPx). As a consequence, the ratio of reduced and oxidized glutathione (GSH:GSSG) serves as a representative marker of the antioxidative capacity of the cell. A deficiency in GSH puts the cell at risk for oxidative damage. An imbalance in GSH is observed in a wide range of pathologies, such as cancer, neurodegenerative diseases, cystic fibrosis (CF), several viral infections including HIV-1, as well as in aging. Several reports have provided evidence for the use of GSH and molecules able to replenish intracellular GSH levels in antiviral therapy. This non-conventional role of GSH and its analogs as antiviral drugs is discussed in this chapter.

Download full-text


Available from: Alessandra Fraternale, Aug 28, 2014
53 Reads
  • Source
    • "Budak). immune deficiency syndrome (AIDS) (Fraternale et al., 2009), Parkinson's disease (Gironi et al., 2011), Alzheimer's disease (Tchaikovskaya et al., 2005), diabetes (Mari et al., 2010; Raza, 2011), apoptosis (Adler and Pincus, 2004; Simic et al., 2009) and aging (Tchaikovskaya et al., 2005). The glutathione S-transferases (EC "
    [Show abstract] [Hide abstract]
    ABSTRACT: The glutathione S-transferases (EC were purified and characterized from turkey liver for the first time. The enzyme was purified 252.7-fold with a yield of 45%, with a specific activity of 164.31U/mg from turkey liver. The purity of the enzyme was determined by SDS-PAGE and showed two bands nearly 26kDa and 24kDa on the gel. The native molecular mass of the enzyme was found to be approximately 53kDa by Sephadex G-100 gel filtration chromatography. Optimal pH, stable pH, optimal temperature, optimum ionic strength, K(m) and V(max) values for GSH and CDNB were also determined for the enzyme as 7.3, 8.5, 50°C, 600mM, 0.154mM, 0.380mM, 1.803EU/ml, and 2.125EU/ml, respectively. Additionally, inhibitory effects of metal ions (Cu(2+), Hg(2+), Fe(2+), Zn(2+), Ag(+), Mg(2+), Ni(2+), and Mn(2+)) were examined the enzyme's activity in vitro by performing Lineweaver-Burk graphs and plotting activity% vs., respectively.
    08/2012; 34(3). DOI:10.1016/j.etap.2012.08.010
  • Source
    • "Oxidative stress is implicated in the pathogenesis and morbidity of HIV infection [19], [20]. An increase of ROS and an alteration of antioxidant defenses have been reported in HIV-infected patients [21] associated with decreased levels of antioxidants [22]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The intestinal mucosa is an important target of human immunodeficiency virus (HIV) infection. HIV virus induces CD4+ T cell loss and epithelial damage which results in increased intestinal permeability. The mechanisms involved in nutrient malabsorption and alterations of intestinal mucosal architecture are unknown. We previously demonstrated that HIV-1 transactivator factor (Tat) induces an enterotoxic effect on intestinal epithelial cells that could be responsible for HIV-associated diarrhea. Since oxidative stress is implicated in the pathogenesis and morbidity of HIV infection, we evaluated whether Tat induces apoptosis of human enterocytes through oxidative stress, and whether the antioxidant N-acetylcysteine (NAC) could prevent it. Caco-2 and HT29 cells or human intestinal mucosa specimens were exposed to Tat alone or combined with NAC. In an in-vitro cell model, Tat increased the generation of reactive oxygen species and decreased antioxidant defenses as judged by a reduction in catalase activity and a reduced (GSH)/oxidized (GSSG) glutathione ratio. Tat also induced cytochrome c release from mitochondria to cytosol, and caspase-3 activation. Rectal dialysis samples from HIV-infected patients were positive for the oxidative stress marker 8-hydroxy-2'-deoxyguanosine. GSH/GSSG imbalance and apoptosis occurred in jejunal specimens from HIV-positive patients at baseline and from HIV-negative specimens exposed to Tat. Experiments with neutralizing anti-Tat antibodies showed that these effects were direct and specific. Pre-treatment with NAC prevented Tat-induced apoptosis and restored the glutathione balance in both the in-vitro and the ex-vivo model. These findings indicate that oxidative stress is one of the mechanism involved in HIV-intestinal disease.
    PLoS ONE 12/2011; 6(12):e29436. DOI:10.1371/journal.pone.0029436 · 3.23 Impact Factor
  • Source
    • "The utility of GSH in antiviral therapies has been shown (Fraternale et al., 2009). Thus, nonradical based redox therapies represent an opportunity in the development of cancer drugs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Imbalances in cancer cell redox homeostasis provide a platform for new opportunities in the development of anticancer drugs. The control of severe dose-limiting toxicities associated with redox regulation, including myelosuppression and immunosuppression, remains a challenge. Recent evidence implicates a critical role for redox regulation and thiol balance in pathways that control myeloproliferation, hematopoietic progenitor cell mobilization, and immune response. Hematopoietic stem cell (HSC) self-renewal and differentiation are dependent upon levels of intracellular reactive oxygen species (ROS) and niche microenvironments. Redox status and the equilibrium of free thiol:disulfide couples are important in modulating immune response and lymphocyte activation, proliferation and differentiation. This subject matter is the focus of the present review. The potential of redox modulating chemotherapeutics as myeloproliferative and immunomodulatory agents is also covered.
    Pharmacology [?] Therapeutics 10/2010; 129(2):172-84. DOI:10.1016/j.pharmthera.2010.09.008 · 9.72 Impact Factor
Show more